Connect
← Return to just diagnosed 2 mos ago Gleason 8 2 lymph nodes
Discussion
just diagnosed 2 mos ago Gleason 8 2 lymph nodes
Prostate Cancer | Last Active: Aug 21 2:19am | Replies (45)Comment receiving replies
I think I am having the EBRT..prob 40 or so sessions starting late Sept...I have 4 areas on prostate and 2 pelvic lymph nodes...
so can I ask what your diagnosis was ?? you seem to be holding up very well...I think your advice and exp is helpful since you have been dealing with PC for a while.. but good news is you are still here..hope that life for you is returned somewhat to your normal..I am not there yet but feel more hopeful now than I was late May thru early August- a new record low period in my life..and I have had a few- not from cancer but other things...PC diagnosis and being mostly abandoned by my urologist was very tough
Replies to "I think I am having the EBRT..prob 40 or so sessions starting late Sept...I have 4..."
Connect
In 2010 I was 62 and a biopsy showed Gleason 3+4. Had surgery, after surgery they told me it was a 4+3. It was only stage two. 3.5 Years later it came back and I had radiation. 2 1/2 years later it came back and I went on Lupron. I became castrate resistant 2.5 years later and added biclautamide. 1 year later went on Zytiga, which kept my PSA down for 2 1/2 years., After some AFIB Issues I switched over to Nubeqa, The last 20 months I’ve been undetectable. I became stage four about six years ago, had a metastasis on my spine zapped. I did not find out I was BRCA2 Until four years ago. That’s why it keeps coming back.
I became mCRPC (castrate resistant 6 years ago. Here is life expectancy information about that. Sometimes I think I may be on borrowed time.
Median Survival: While the median overall survival (OS) for mCRPC patients is often cited as around two years, it's crucial to understand that this is a median, meaning that half of patients live longer than this, and half live for a shorter duration.
Individual Variation: Survival times vary greatly among mCRPC patients, influenced by factors like the extent of the disease (where it has spread, whether it is high volume or low volume disease, etc.), overall health, and response to treatment.